5-bromo-4-iodo-2-(trifluoromethyl)pyridine | 1025509-75-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-bromo-4-iodo-2-(trifluoromethyl)pyridine
• CAS: 1025509-75-4
• 化学式: C₆H₂BrF₃IN
• 分子量: 351.892
• InChiKey: CQTRWNRVSWLXGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-bromo-4-iodo-2-(trifluoromethyl)pyridine 在 盐酸 、 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 乙醇 、 水 、 甲苯 为溶剂， 反应 60.0h， 生成 N4-ethyl-6-(trifluoromethyl)pyridine-3,4-diamine
  参考文献：
  名称：

  Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity

  摘要：

  We report here a novel series of benzimidazole sulfonamides that act as antagonists of the S1P(1) receptor, identified by exploiting an understanding of the pharmacophore of a high throughput screening (HTS)-derived series of compounds described previously. Lead compound 2 potently inhibits SIP-induced receptor internalization in a cell-based assay (EC50 = 0.05 mu M), but has poor physical properties and metabolic stability. Evolution of this compound through structure-activity relationship development and property optimization led to in vivo probes such as 4. However, this compound was unexpectedly found to be a potent CYP3A inducer in human hepatocytes, and thus further chemistry efforts were directed at addressing this liability. By employing a pregnane X receptor (PXR) reporter gene assay to prioritize compounds for further testing in human hepatocytes, we identified lipophilicity as a key molecular property influencing the likelihood of P450 induction. Ultimately, we have identified compounds such as 46 and 47, which demonstrate the desired S1P(1) antagonist activity while having greatly reduced risk of CYP3A induction in humans. These compounds have excellent oral bioavailability in preclinical species and exhibit pharmacodynamic effects of S1P(1) antagonism in several in vivo models following oral dosing. Relatively modest antitumor activity was observed in multiple xenograft models, however, suggesting that selective S1P(1) antagonists would have limited utility as anticancer therapeutics as single agents.

  DOI：

  10.1021/acs.jmedchem.5b01078
• 作为产物：
  描述：

  5-溴-2-三氟甲基吡啶 在 正丁基锂 、 二异丙胺 、 碘 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.0h， 以40%的产率得到5-bromo-4-iodo-2-(trifluoromethyl)pyridine
  参考文献：
  名称：

  碱催化卤素转移实现杂芳烃的亲核 C-H 醚化

  摘要：

  我们报告了N-杂芳烃直接 C-H 醚化的一般方案。叔丁醇钾催化卤素从 2-卤代噻吩转移到N-杂芳烃以形成N-杂芳基卤化物中间体，该中间体经历串联碱促进的醇取代。因此，简单地包含廉价的 2-卤代噻吩能够在碱性反应条件下实现醇与 1,3-唑、吡啶、二嗪和多嗪的区域选择性氧化偶联。

  DOI：

  10.1021/jacs.1c06481

文献信息

• HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY
  申请人：Grewal Gurmit

  公开号：US20100029643A1

  公开（公告）日：2010-02-04

  The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.

  该发明涉及化学式（I），（Ia）和（Ib）或其药学上可接受的盐的化合物，其具有Edg-1拮抗活性，因此在抗癌活性和人或动物体的治疗方法中有用。该发明还涉及制造上述化学化合物的过程，含有它们的制药组合物以及在制造用于在温血动物（如人）中产生抗癌效果的药物的制造中使用它们。
• Regio-controllable [2+2] benzannulation with two adjacent C(sp ³ )–H bonds
  作者：Ji-Min Yang、Yu-Kun Lin、Tao Sheng、Liang Hu、Xin-Pei Cai、Jin-Quan Yu

  DOI：10.1126/science.adg5282

  日期：2023.5.12

  amide-pyridone ligands, to achieve a regio-controllable synthesis of BCBs through a formal [2+2] cycloaddition involving σ bonds only (two C–H bonds and two aryl–halogen bonds). A wide range of cyclic and acyclic aliphatic acids, as well as dihaloheteroarenes, are compatible, generating diversely functionalized BCBs and hetero-BCBs present in drug molecules and bioactive natural products.

  不饱和碳化合物之间的传统环加成反应中的区域控制通常具有挑战性。现代药物化学对苯并环丁烯 (BCB) 支架的日益关注表明，需要寻找替代的、更具选择性的途径来制备富含 C(sp 3 ） 特点。在这里，我们报道了由二齿酰胺-吡啶酮配体实现的钯催化的羧酸中两个相邻亚甲基单元的双C-H活化，通过涉及σ的正式[2+2]环加成实现了BCB的区域可控合成。仅键（两个 C-H 键和两个芳基-卤素键）。多种环状和无环脂肪酸以及二卤杂芳烃是相容的，可生成药物分子和生物活性天然产物中存在的多种功能化的 BCB 和杂 BCB。
• HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP2094670A1

  公开（公告）日：2009-09-02
• [EN] HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY<br/>[FR] SULFONAMIDES HÉTÉROCYCLIQUES À ACTIVITÉ ANTAGONISTE DE EDG-1
  申请人：ASTRAZENECA AB

  公开号：WO2008056150A1

  公开（公告）日：2008-05-15

  [EN] The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.
  [FR] L'invention porte sur des composés chimiques de formule (I), (Ia) et (Ib) ou sur des sels pharmaceutiquement acceptables de ceux-ci, qui possèdent une activité antagoniste de Edg-1 et sont en conséquence utiles pour leur activité anti-cancer et donc dans des procédés de traitement du corps humain ou animal. L'invention porte également sur des procédés de fabrication desdits composés chimiques, sur des compositions pharmaceutiques les contenant et sur leur utilisation dans la fabrication de médicaments utilisés pour produire un effet anti-cancer chez un animal à sang chaud, tel que l'homme.